Published in Cell on February 14, 2013
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature (2014) 2.91
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature (2017) 2.54
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med (2015) 2.29
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood (2013) 2.18
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell (2014) 2.15
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Mutations driving CLL and their evolution in progression and relapse. Nature (2015) 2.06
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet (2014) 2.02
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov (2014) 1.99
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med (2015) 1.98
THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. Genome Biol (2013) 1.98
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 1.92
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet (2015) 1.82
Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol (2015) 1.82
Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia (2014) 1.81
Divergent clonal selection dominates medulloblastoma at recurrence. Nature (2016) 1.81
Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 1.79
Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov (2015) 1.76
Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A (2015) 1.72
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med (2013) 1.68
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia (2013) 1.66
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med (2015) 1.64
Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics (2014) 1.62
Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet (2014) 1.60
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet (2014) 1.58
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood (2015) 1.56
Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood (2014) 1.55
Making sense of big data in health research: Towards an EU action plan. Genome Med (2016) 1.55
MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. Cell Stem Cell (2016) 1.54
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics (2014) 1.53
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov (2015) 1.51
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood (2016) 1.47
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2015) 1.47
Development of a Comprehensive Genotype-to-Fitness Map of Adaptation-Driving Mutations in Yeast. Cell (2016) 1.47
TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res (2014) 1.45
High-definition reconstruction of clonal composition in cancer. Cell Rep (2014) 1.45
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol (2014) 1.44
Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. Br J Haematol (2015) 1.41
Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res (2014) 1.40
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol (2016) 1.39
Reference-free inference of tumor phylogenies from single-cell sequencing data. BMC Genomics (2015) 1.38
Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36
SAMHD1-dependent retroviral control and escape in mice. EMBO J (2013) 1.36
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med (2013) 1.26
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A (2015) 1.24
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res (2015) 1.22
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov (2014) 1.21
Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet (2014) 1.18
PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol (2015) 1.17
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res (2013) 1.15
Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A (2014) 1.14
Fast and scalable inference of multi-sample cancer lineages. Genome Biol (2015) 1.13
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia (2014) 1.13
SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol (2014) 1.12
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 1.11
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov (2013) 1.11
The evolution of drug resistance in clinical isolates of Candida albicans. Elife (2015) 1.10
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov (2015) 1.10
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood (2014) 1.09
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia (2013) 1.08
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One (2013) 1.06
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet (2016) 1.06
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Mod Pathol (2016) 1.05
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget (2015) 1.03
Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology. CPT Pharmacometrics Syst Pharmacol (2013) 1.03
An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform (2014) 1.03
Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med (2014) 1.02
Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia (2014) 1.02
The evolutionary biography of chronic lymphocytic leukemia. Nat Genet (2013) 1.02
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet (2016) 1.01
Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood (2015) 1.01
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med (2016) 1.01
The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol (2013) 1.01
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica (2014) 1.01
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med (2013) 1.01
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Clonal evolution in cancer. Nature (2012) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
The life history of 21 breast cancers. Cell (2012) 10.59
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Evolutionary dynamics of biological games. Science (2004) 5.99
Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet (2009) 5.84
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood (2012) 3.63
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood (2008) 2.35
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst (1999) 2.13
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica (2007) 1.99
Lessons from the past: evolutionary impacts of mass extinctions. Proc Natl Acad Sci U S A (2001) 1.88
Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res (2011) 1.83
Mammalian linker-histone subtypes differentially affect gene expression in vivo. Proc Natl Acad Sci U S A (2003) 1.37
EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene (2003) 1.34
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.33
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood (2003) 1.28
An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol (2008) 1.26
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol (2008) 1.24
MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood (2006) 0.99
CLL clonal heterogeneity: an ecology of competing subpopulations. Blood (2012) 0.97
Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res (2009) 0.94
Inositol 1,4,5-trisphosphate 3-kinase B controls survival and prevents anergy in B cells. Immunobiology (2010) 0.89
The use of molecular markers in selecting therapy for CLL. Clin Adv Hematol Oncol (2005) 0.88
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat Biotechnol (2011) 53.86
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol (2010) 18.44
The mammalian epigenome. Cell (2007) 18.13
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet (2003) 16.51
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48